• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phreesia Announces First Quarter Fiscal 2027 Results

    5/27/26 4:03:00 PM ET
    $PHR
    Real Estate
    Real Estate
    Get the next $PHR alert in real time by email

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2026.

    "Phreesia had a solid first quarter to build on in fiscal 2027. We entered the new fiscal year with an experienced team, a strong financial profile and continued momentum across several key initiatives, including positioning AccessOne for future growth, the successful launch of our healthcare provider (HCP) marketing offerings and the infusion of AI into the Phreesia operating model," said CEO and Co-Founder Chaim Indig.

    Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal 2027 Stakeholder Letter.

    Fiscal First Quarter Ended April 30, 2026 Highlights

    • Total revenue was $130.9 million in the quarter, up 13% year-over-year.
    • Average number of healthcare services clients ("AHSCs") was 4,708 in the quarter, up 7% year-over-year.
    • Total revenue per AHSC was $27,811 in the quarter, up 6% year-over-year. See "Key Metrics" below for additional information.
    • Net income was $3.0 million in the quarter, as compared to net loss of $3.9 million in the same period in the prior year.
    • Adjusted EBITDA1 was $30.5 million in the quarter, as compared to $20.8 million in the same period in the prior year.
    • Net cash provided by operating activities was $23.9 million in the quarter, as compared to $14.9 million in the same period in the prior year.
    • Free cash flow2 was $16.4 million in the quarter, as compared to $7.5 million in the same period in the prior year.
    • Cash, cash equivalents and restricted cash as of April 30, 2026 was $76.4 million, an increase of $2.6 million from January 31, 2026. As of April 30, 2026, cash, cash equivalents and restricted cash included $1.7 million of long-term restricted cash classified within other long-term assets.

    Recent Developments

    New Capital One Credit Agreement and Refinancing

    On March 13, 2026, we completed a refinancing pursuant to which we terminated without penalty and repaid all outstanding indebtedness and obligations under the Bridge Loan (as defined below) with $92.2 million of borrowings from a new 5-year, $275 million senior secured revolving credit facility (the "New Capital One Credit Facility") maturing on March 13, 2031. The Bridge Loan, a 364-day, $110 million secured term loan entered into on November 12, 2025 (the "Bridge Loan"), was used to fund a portion of the consideration for the acquisition of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, "AccessOne" and such acquisition, the "AccessOne Acquisition"). The New Capital One Credit Facility also replaced our previous credit facility with Capital One, which had no outstanding borrowings and was terminated on the same date. The unused borrowing capacity on the New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes.

    For more information regarding the New Capital One Credit Facility and the termination of the Bridge Loan and the Previous Capital One Credit Facility, please see our Current Report on Form 8-K filed with the SEC on March 16, 2026.

    AccessOne Securitization Program Expansion

    On April 30, 2026, we entered into an amendment (the "Amendment") to the agreement governing AccessOne's securitization facility with PNC Bank (the "Securitization Program"). The Securitization Program supports AccessOne's ability to offer patients flexible payment plans while providing up-front cash to healthcare providers for eligible patient receivables. The Amendment extended the term of the Securitization Program through April 30, 2029 and increased the facility limit from $200 million to $300 million, expanding our capacity to bring AccessOne's financing capabilities to more healthcare services clients. The Amendment also amended certain covenants, allowing us to offer upfront receivables funding to a greater portion of our provider network — including non-investment grade organizations like community hospitals and specialty practices that are central to our growth strategy for AccessOne.

    In connection with the Amendment, Phreesia, AccessOne Holdings, Inc. ("AccessOne Holdings") and PNC Bank entered into an Amended and Restated Performance Guaranty (the "Guaranty"), pursuant to which Phreesia became a joint and several co-guarantor of AccessOne MedCard's obligations under certain transaction documents. The Guaranty expressly provides that it is not a guarantee of the collection of any pool receivables and that Phreesia and AccessOne Holdings are not responsible for any non-payment or delay in the payment of any pool receivables solely due to the insolvency, bankruptcy, lack of creditworthiness or other financial inability to pay of the related obligor or provider.

    For more information regarding the Amendment and the Guaranty, please see our Current Report on Form 8-K filed with the SEC on May 4, 2026.

    Fiscal 2027 Outlook

    We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted last quarter, network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December. Certain clients are committing fewer dollars due to brand-specific dynamics including the impact of regulatory policies. Though we do not believe these developments are signaling a structural shift in demand for Phreesia's solutions, there is now more variability in our internal network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in March 2026. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027.

    We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. In addition to our continued belief in the operating leverage embedded in our model, we have more recently identified opportunities to reduce our reliance on manual processes across Phreesia through the adoption of artificial intelligence. In May 2026, subsequent to quarter end, we implemented a restructuring plan intended to reduce operating expenses and better align our cost structure with our current business priorities. The plan is expected to result in meaningful annualized run-rate expense savings, which were reflected in our Adjusted EBITDA outlook provided on March 30, 2026.

    We are maintaining our expectation for AHSC growth in the mid-single-digit percent range, and we are maintaining our outlook for total revenue per AHSC to grow in the low-single-digit percent range, respectively, in fiscal 2027.

    We believe our cash, cash equivalents, restricted cash and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations. As of April 30, 2026 we had $84.2 million in borrowings outstanding under the New Capital One Credit Facility.

    Non-GAAP3 Financial Measures

    We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see "Non-GAAP Financial Measures" below.

    Available Information

    We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Forward Looking Statements

    This press release includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding our restructuring plan, reductions in operating expenses and resulting expense savings; the expected results of the AccessOne Acquisition discussed herein, including anticipated additional revenue, Adjusted EBITDA and AHSCs; our ability to finance our plans to achieve our fiscal 2027 outlook with our current cash balance, cash generated in the normal course of business; our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC; our growth strategies for the AccessOne business; our ability to offer the AccessOne solution to additional clients and access to capital; our expectations regarding opportunities to reduce reliance on manual processes across the Company through the adoption of artificial intelligence; and expectations regarding our restructuring plan, reductions in operating expenses and annualized run-rate expense savings. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in our New Capital One Credit Facility and the Securitization Program; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission ("SEC"), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

    This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

    Conference Call Information

    We will hold a conference call on Wednesday, May 27, 2026 at 5:00 p.m. Eastern Time to review our fiscal 2027 first quarter financial results. To participate in our live conference call and webcast, please dial (833) 461-5787 (or (626) 884-3620 for international participants) using conference code number 953036497 or visit the "Events & Presentations" section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Phreesia

    Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

    Phreesia, Inc.

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

     

     

    April 30, 2026

     

    January 31, 2026

     

    (Unaudited)

     

     

    Assets

     

     

     

    Current:

     

     

     

    Cash, cash equivalents and restricted cash (including restricted cash of $— and $1,691 as of April 30, 2026 and January 31, 2026, respectively)

    $

    74,706

     

     

    $

    73,830

     

    Settlement assets

     

    32,720

     

     

     

    32,999

     

    Accounts receivable, net of allowance for doubtful accounts of $1,467 and $1,523 as of April 30, 2026 and January 31, 2026, respectively

     

    89,607

     

     

     

    97,453

     

    Cardholder receivables

     

    29,740

     

     

     

    38,330

     

    Deferred purchase price receivables

     

    23,247

     

     

     

    18,003

     

    Accrued interest and fees receivables

     

    711

     

     

     

    840

     

    Deferred contract acquisition costs

     

    401

     

     

     

    410

     

    Prepaid expenses and other current assets

     

    16,129

     

     

     

    17,978

     

    Total current assets

     

    267,261

     

     

     

    279,843

     

    Property and equipment, net of accumulated depreciation and amortization of $90,385 and $94,193 as of April 30, 2026 and January 31, 2026, respectively

     

    20,568

     

     

     

    20,332

     

    Capitalized internal-use software, net of accumulated amortization of $73,362 and $69,390 as of April 30, 2026 and January 31, 2026, respectively

     

    54,624

     

     

     

    54,270

     

    Operating lease right-of-use assets

     

    1,769

     

     

     

    2,002

     

    Deferred contract acquisition costs

     

    231

     

     

     

    338

     

    Intangible assets, net of accumulated amortization of $16,099 and $13,489 as of April 30, 2026 and January 31, 2026, respectively

     

    77,151

     

     

     

    79,761

     

    Goodwill

     

    169,513

     

     

     

    170,064

     

    Deferred tax assets

     

    1,593

     

     

     

    1,593

     

    Other assets (includes $1,691 and $— of long-term restricted cash as of April 30, 2026 and January 31, 2026, respectively)

     

    7,283

     

     

     

    2,442

     

    Long-term cardholder receivables

     

    59,494

     

     

     

    47,723

     

    Long-term deferred purchase price receivables

     

    6,654

     

     

     

    5,422

     

    Total Assets

    $

    666,141

     

     

    $

    663,790

     

    Liabilities and Stockholders' Equity

     

     

     

    Current:

     

     

     

    Settlement obligations

    $

    32,720

     

     

    $

    32,999

     

    Current portion of debt and finance lease liabilities

     

    5,301

     

     

     

    7,971

     

    Current portion of operating lease liabilities

     

    1,062

     

     

     

    1,254

     

    Accounts payable

     

    11,891

     

     

     

    11,477

     

    Accrued expenses

     

    30,521

     

     

     

    41,257

     

    Due to healthcare providers

     

    30,331

     

     

     

    38,056

     

    Deferred revenue

     

    39,561

     

     

     

    49,522

     

    Other current liabilities

     

    722

     

     

     

    705

     

    Total current liabilities

     

    152,109

     

     

     

    183,241

     

    Long-term debt and finance lease liabilities

     

    85,303

     

     

     

    92,117

     

    Operating lease liabilities, non-current

     

    891

     

     

     

    1,107

     

    Long-term due to healthcare providers

     

    60,826

     

     

     

    45,329

     

    Long-term deferred revenue

     

    3,223

     

     

     

    244

     

    Long-term deferred tax liabilities

     

    4,624

     

     

     

    4,498

     

    Other long-term liabilities

     

    75

     

     

     

    47

     

    Total Liabilities

     

    307,051

     

     

     

    326,583

     

    Commitments and contingencies

     

     

     

    Stockholders' Equity:

     

     

     

    Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both April 30, 2026 and January 31, 2026; no shares issued or outstanding as of both April 30, 2026 and January 31, 2026

     

    —

     

     

     

    —

     

    Common stock, $0.01 par value—500,000,000 shares authorized as of both April 30, 2026 and January 31, 2026; 63,249,229 and 62,020,186 shares issued as of April 30, 2026 and January 31, 2026, respectively

     

    632

     

     

     

    620

     

    Additional paid-in capital

     

    1,201,871

     

     

     

    1,181,679

     

    Accumulated deficit

     

    (796,227

    )

     

     

    (799,190

    )

    Accumulated other comprehensive loss

     

    (571

    )

     

     

    (382

    )

    Treasury stock, at cost, 1,474,884 and 1,355,169 shares as of April 30, 2026 and January 31, 2026, respectively

     

    (46,615

    )

     

     

    (45,520

    )

    Total Stockholders' Equity

     

    359,090

     

     

     

    337,207

     

    Total Liabilities and Stockholders' Equity

    $

    666,141

     

     

    $

    663,790

     

    Phreesia, Inc.

    Unaudited Consolidated Statements of Operations

    (in thousands, except share and per share data)

     

     

    Three months ended

    April 30,

     

    2026

     

    2025

    Revenue:

     

     

     

    Subscription and related services

    $

    52,721

     

     

    $

    54,355

     

    Payment solutions(1)

     

    41,941

     

     

     

    29,925

     

    Network solutions

     

    36,273

     

     

     

    31,656

     

    Total revenues

     

    130,935

     

     

     

    115,936

     

    Expenses:

     

     

     

    Cost of revenue (excluding depreciation and amortization)

     

    17,659

     

     

     

    16,637

     

    Payment solutions expense(1)

     

    25,675

     

     

     

    21,428

     

    Sales and marketing

     

    24,209

     

     

     

    26,043

     

    Research and development

     

    28,328

     

     

     

    31,829

     

    General and administrative

     

    18,361

     

     

     

    16,408

     

    Depreciation

     

    3,371

     

     

     

    2,986

     

    Amortization

     

    6,583

     

     

     

    3,892

     

    Total expenses

     

    124,186

     

     

     

    119,223

     

    Operating income (loss)

     

    6,749

     

     

     

    (3,287

    )

    Other (expense) income, net

     

    (7

    )

     

     

    338

     

    Loss on extinguishment of debt

     

    (17

    )

     

     

    —

     

    Interest expense

     

    (2,299

    )

     

     

    (435

    )

    Interest income

     

    297

     

     

     

    205

     

    Total other (expense) income, net

     

    (2,026

    )

     

     

    108

     

    Income (loss) before income tax expense

     

    4,723

     

     

     

    (3,179

    )

    Income tax expense

     

    (1,760

    )

     

     

    (735

    )

    Net income (loss)

    $

    2,963

     

     

    $

    (3,914

    )

    Net income (loss) per share attributable to common stockholders:

     

     

     

    Basic

    $

    0.05

     

     

    $

    (0.07

    )

    Diluted

    $

    0.05

     

     

    $

    (0.07

    )

    Weighted-average common shares outstanding:

     

     

     

    Basic

     

    60,944,962

     

     

     

    58,920,782

     

    Diluted

     

    62,040,865

     

     

     

    58,920,782

     

    (1) Beginning with the fourth quarter of the fiscal year ended January 31, 2026, the revenue line previously labeled "Payment processing fees" was relabeled "Payment solutions" to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. "Payment solutions" includes all revenue previously presented as "Payment processing fees" and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, "Payment processing expense" was relabeled "Payment solutions expense" and includes all expenses previously presented as "Payment processing expense" and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

    Phreesia, Inc.

    Unaudited Consolidated Statements of Comprehensive Income (Loss)

    (in thousands)

     

     

    Three months ended

    April 30,

     

    2026

     

    2025

    Net income (loss)

    $

    2,963

     

     

    $

    (3,914

    )

    Other comprehensive (loss) income:

     

     

     

    Net change in unrealized gains on cash flow hedges

     

    (81

    )

     

     

    407

     

    Change in foreign currency translation adjustments

     

    (108

    )

     

     

    28

     

    Other comprehensive (loss) income

     

    (189

    )

     

     

    435

     

    Comprehensive income (loss)

    $

    2,774

     

     

    $

    (3,479

    )

    Phreesia, Inc.

    Unaudited Consolidated Statements of Cash Flows

    (in thousands)

     

     

    Three months ended

    April 30,

     

    2026

     

    2025

    Operating activities:

     

     

     

    Net income (loss)

    $

    2,963

     

     

    $

    (3,914

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    9,954

     

     

     

    6,878

     

    Stock-based compensation expense

     

    13,554

     

     

     

    17,225

     

    Amortization of deferred financing costs

     

    434

     

     

     

    62

     

    Loss on extinguishment of debt

     

    17

     

     

     

    —

     

    Cost of Phreesia hardware purchased by customers

     

    188

     

     

     

    436

     

    Deferred contract acquisition costs amortization

     

    116

     

     

     

    110

     

    Non-cash operating lease expense

     

    233

     

     

     

    215

     

    Deferred taxes

     

    677

     

     

     

    85

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    7,731

     

     

     

    (1,490

    )

    Cash received for sale of receivables

     

    7,711

     

     

     

    —

     

    Accrued interest receivable

     

    129

     

     

     

    —

     

    Prepaid expenses and other assets

     

    828

     

     

     

    (256

    )

    Accounts payable

     

    159

     

     

     

    (1,739

    )

    Accrued expenses and other liabilities

     

    (6,985

    )

     

     

    (891

    )

    Payment of due to provider for receivables sold to securitization

     

    (5,060

    )

     

     

    —

     

    Lease liabilities

     

    (410

    )

     

     

    (252

    )

    Deferred revenue

     

    (8,317

    )

     

     

    (1,619

    )

    Net cash provided by operating activities

     

    23,922

     

     

     

    14,850

     

    Investing activities:

     

     

     

    Collections of cardholder receivables held for investment and deferred purchase price

     

    12,352

     

     

     

    —

     

    Capitalized internal-use software

     

    (3,240

    )

     

     

    (3,888

    )

    Purchases of property and equipment

     

    (4,310

    )

     

     

    (3,504

    )

    Net cash provided by (used in) investing activities

     

    4,802

     

     

     

    (7,392

    )

    Financing activities:

     

     

     

    Proceeds from issuance of common stock upon exercise of stock options

     

    131

     

     

     

    128

     

    Treasury stock to satisfy tax withholdings on stock compensation awards

     

    (1,095

    )

     

     

    —

     

    Proceeds from employee stock purchase plan

     

    522

     

     

     

    768

     

    Finance lease payments

     

    (1,680

    )

     

     

    (1,376

    )

    Principal payments on financing agreements

     

    (355

    )

     

     

    (320

    )

    Debt issuance costs and loan facility fee payments

     

    (2,259

    )

     

     

    (38

    )

    Financing payments of acquisition-related liabilities

     

    —

     

     

     

    —

     

    Debt extinguishment costs

     

    (42

    )

     

     

    —

     

    Proceeds from debt instruments

     

    92,240

     

     

     

    —

     

    Principal payments on debt instruments

     

    (98,000

    )

     

     

    —

     

    Payments due to provider for unfunded receivables

     

    (15,555

    )

     

     

    —

     

    Net cash used in financing activities

     

    (26,093

    )

     

     

    (838

    )

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

    (64

    )

     

     

    31

     

    Net increase in cash, cash equivalents and restricted cash

     

    2,567

     

     

     

    6,651

     

    Cash, cash equivalents and restricted cash – beginning of period

     

    73,830

     

     

     

    84,220

     

    Cash, cash equivalents and restricted cash – end of period

    $

    76,397

     

     

    $

    90,871

     

     

     

     

     

    Supplemental information of non-cash investing and financing information:

     

     

     

    Non-cash activity related to credit card receivables and deferred purchase price

    $

    27,717

     

     

    $

    —

     

    Exchange of right of use asset for property and equipment

    $

    57

     

     

    $

    —

     

    Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities

    $

    2,304

     

     

    $

    1,117

     

    Capitalized stock-based compensation

    $

    342

     

     

    $

    332

     

    Issuance of stock to settle liabilities for stock-based compensation

    $

    8,053

     

     

    $

    6,508

     

    Cash paid for:

     

     

     

    Interest

    $

    3,848

     

     

    $

    324

     

    Income taxes

    $

    1,181

     

     

    $

    551

     

     

     

     

     

    Reconciliation of cash, cash equivalents and restricted cash shown in statements of cash flows

     

     

     

    Cash, cash equivalents and restricted cash per balance sheets

    $

    74,706

     

     

    $

    90,871

     

    Restricted cash included in other long-term assets

     

    1,691

     

     

     

    —

     

    Total cash, cash equivalents and restricted cash shown in statements of cash flows

    $

    76,397

     

     

    $

    90,871

     

     

     

     

     

    Non-GAAP Financial Measures

    This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

    Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three and nine months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted.

    We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

    We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

    Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

    • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
    • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other expense (income), net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and
    • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

    Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss), and our GAAP financial results.

    The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

    Phreesia, Inc.

    Adjusted EBITDA

     

     

    Three months ended

    April 30,

    (in thousands, unaudited)

    2026

     

    2025

    Net income (loss)

    $

    2,963

     

     

    $

    (3,914

    )

    Interest expense

     

    2,299

     

     

     

    435

     

    Interest income

     

    (297

    )

     

     

    (205

    )

    Income tax expense

     

    1,760

     

     

     

    735

     

    Depreciation and amortization

     

    9,954

     

     

     

    6,878

     

    Stock-based compensation expense

     

    13,554

     

     

     

    17,225

     

    Loss on extinguishment of debt

     

    17

     

     

     

    —

     

    Other expense (income), net

     

    7

     

     

     

    (338

    )

    Other items affecting comparability(1)

     

    217

     

     

     

    —

     

    Adjusted EBITDA

    $

    30,474

     

     

    $

    20,816

     

    (1) For the three months ended April 30, 2026, consisted of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition.

    We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

    Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position.

    The following table presents a reconciliation of free cash flow from net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

    Phreesia, Inc.

    Free cash flow

     

     

    Three months ended

    April 30,

    (in thousands, unaudited)

    2026

     

    2025

    Net cash provided by operating activities

    $

    23,922

     

     

    $

    14,850

     

    Less:

     

     

     

    Capitalized internal-use software

     

    (3,240

    )

     

     

    (3,888

    )

    Purchases of property and equipment

     

    (4,310

    )

     

     

    (3,504

    )

    Free cash flow

    $

    16,372

     

     

    $

    7,458

     

    Phreesia, Inc.

    Supplementary Information

    (Unaudited)

     

     

    Three months ended

    April 30,

    (in thousands)

    2026

     

    2025

    GAAP operating expenses

     

     

     

    General and administrative

    $

    18,361

     

    $

    16,408

    Sales and marketing

     

    24,209

     

     

    26,043

    Research and development

     

    28,328

     

     

    31,829

    Cost of revenue (excluding depreciation and amortization)

     

    17,659

     

     

    16,637

     

    $

    88,557

     

    $

    90,917

    Stock compensation included in GAAP operating expenses

     

     

     

    General and administrative

    $

    5,489

     

    $

    6,573

    Sales and marketing

     

    3,902

     

     

    5,174

    Research and development

     

    3,565

     

     

    4,393

    Cost of revenue (excluding depreciation and amortization)

     

    598

     

     

    1,085

     

    $

    13,554

     

    $

    17,225

    Acquisition-related costs included in GAAP operating expenses

     

     

     

    General and administrative

    $

    217

     

    $

    —

    Phreesia, Inc.

    Key Metrics

    (Unaudited)

     

     

    Three months ended

    April 30,

     

    2026

     

    2025

    Average number of healthcare services clients ("AHSCs")

     

    4,708

     

     

    4,411

    Total revenue per AHSC

    $

    27,811

     

    $

    26,283

    The definitions of our key metrics are presented below.

    • AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients.
    • Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment solutions revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions.

    Phreesia, Inc.

    Additional Information

    (Unaudited)

     

     

    Three months ended

     

    April 30,

    2026

     

    January 31,

    2026(1)

    Total managed payments (in billions)

    $

    1.786

     

     

    $

    1.560

     

    Payment solutions revenue rate

     

    2.3

    %

     

     

    2.3

    %

    (1) The AccessOne Acquisition was completed on November 12, 2025. Reflects inclusion of the business operations of AccessOne from November 12, 2025 to January 31, 2026 and therefore the payment solutions revenue rate for the three months ended January 31, 2026 is not indicative of AccessOne's full-quarter performance.

    We are introducing new metrics: total managed payments and payment solutions revenue rate. We believe these new metrics will enable investors to better evaluate the performance of our payment solutions business following the AccessOne Acquisition during the fourth quarter of fiscal 2026, which introduced new revenue-generating activities. These metrics replace patient payment volume and payment facilitator volume percentage, which reflected only the legacy Phreesia payment processing business4. Total managed payments reflects both the transactional activity we facilitate and the financing solutions we provide to healthcare organizations and patients. These metrics provide a clear and consistent framework for understanding how payment activity translates into revenue, enabling investors to more effectively assess the growth, performance and overall value of our payment solutions business.

    • Total managed payments. We define total managed payments as the sum of (i) our legacy patient payment volume, measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors; and (ii) the average month-end outstanding balance of our managed portfolio of cardholder receivables, calculated as the average of the month-end balances during the applicable period. We believe total managed payments are a useful indicator of the scale and health of our payments ecosystem, reflecting both the volume of transactions we facilitate and the size of the receivables portfolio we service. Total managed payments are one of the primary drivers of our total payments revenue.
    • Payment solutions revenue rate. We define our payment solutions revenue rate as total payment solutions revenue divided by total managed payments for a given period. This rate reflects the combined monetization of both our payment processing and patient financing activities in a single, unified rate. We believe this metric provides a useful lens into the efficiency and stability of our revenue model over time, enabling investors to better understand how changes in volume and portfolio size translate into revenue and to more easily evaluate the underlying performance and scalability of our payment solutions business. Because total managed payments includes both transaction volume and average receivables balances, payment solutions revenue rate should not be interpreted as a processing take rate, interest yield or margin. 

    _________________

    1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of Fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See "Non-GAAP Financial Measures" for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

    2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See "Non-GAAP Financial Measures" for a reconciliation of free cash flow to the closest GAAP measure.

    3 GAAP is defined as generally accepted accounting principles in the United States.

    4 For periods prior to the three months ended April 30, 2026, we presented (i) patient payment volume (measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors) and (ii) payment facilitator volume percentage (defined as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume).

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260527895201/en/

    Investor Relations Contact:

    Balaji Gandhi

    Phreesia, Inc.

    investors@phreesia.com

    (929) 506-4950

    Media Contact:

    Nicole Gist

    Phreesia, Inc.

    nicole.gist@phreesia.com

    (407) 760-6274

    Get the next $PHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHR

    DatePrice TargetRatingAnalyst
    5/28/2026$12.00Overweight → Neutral
    Piper Sandler
    5/20/2026$9.00Overweight → Equal Weight
    Wells Fargo
    5/15/2026$10.00Overweight → Equal Weight
    Barclays
    4/1/2026Mkt Outperform → Mkt Perform
    Citizens
    3/31/2026$10.00Outperform → Neutral
    Robert W. Baird
    3/31/2026$11.00Buy → Hold
    Truist
    3/31/2026$10.00Buy → Neutral
    Citigroup
    3/31/2026$16.00Overweight → Neutral
    Analyst
    More analyst ratings

    $PHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phreesia downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Phreesia from Overweight to Neutral and set a new price target of $12.00

    5/28/26 2:24:34 PM ET
    $PHR
    Real Estate

    Phreesia downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Phreesia from Overweight to Equal Weight and set a new price target of $9.00

    5/20/26 8:06:11 AM ET
    $PHR
    Real Estate

    Phreesia downgraded by Barclays with a new price target

    Barclays downgraded Phreesia from Overweight to Equal Weight and set a new price target of $10.00

    5/15/26 8:26:17 AM ET
    $PHR
    Real Estate

    $PHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phreesia Announces First Quarter Fiscal 2027 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2026. "Phreesia had a solid first quarter to build on in fiscal 2027. We entered the new fiscal year with an experienced team, a strong financial profile and continued momentum across several key initiatives, including positioning AccessOne for future growth, the successful launch of our healthcare provider (HCP) marketing offerings and the infusion of AI into the Phreesia operating model," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal 2027 Stakeholder Letter.

    5/27/26 4:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Sets Release Date for Fiscal First Quarter 2027 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal first quarter 2027 financial results after the close of market trading on Wednesday, May 27, 2026. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (833) 461-5787, or (626) 884-3620 for international participants, using conference code number 953036497, or vi

    5/1/26 6:46:00 AM ET
    $PHR
    Real Estate

    Phreesia Named to Becker's Hospital Review's 2026 List of "Revenue Cycle Management Companies to Know"

    Phreesia, a leader in patient intake, outreach and activation, has been named to Becker's Hospital Review's 2026 list of "Revenue Cycle Management Companies to Know." The annual list recognizes companies that play a critical role in helping healthcare organizations manage the growing complexity of revenue cycle operations, including patient access, intake, billing and reimbursement. The 2026 list highlights organizations driving innovation and performance across the revenue cycle. Phreesia helps providers digitize intake and manage payment workflows before, during and after patient visits, improving collections and reducing manual administrative work. "We're honored to be recognized by

    4/14/26 4:07:00 PM ET
    $PHR
    Real Estate

    $PHR
    SEC Filings

    View All

    $PHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-Q filed by Phreesia Inc.

    10-Q - Phreesia, Inc. (0001412408) (Filer)

    5/28/26 4:01:11 PM ET
    $PHR
    Real Estate

    Phreesia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    5/27/26 4:00:50 PM ET
    $PHR
    Real Estate

    SEC Form DEFA14A filed by Phreesia Inc.

    DEFA14A - Phreesia, Inc. (0001412408) (Filer)

    5/14/26 4:00:39 PM ET
    $PHR
    Real Estate

    Principal Accounting Officer Hui Yvonne sold $3,814 worth of shares (431 units at $8.85) as part of a pre-agreed trading plan and covered exercise/tax liability with 325 shares, decreasing direct ownership by 3% to 23,908 units (SEC Form 4) (for tax liability)

    4 - Phreesia, Inc. (0001412408) (Issuer)

    5/20/26 4:06:50 PM ET
    $PHR
    Real Estate

    Director Cahill Edward L was granted 1,085 shares, increasing direct ownership by 2% to 65,613 units (SEC Form 4)

    4 - Phreesia, Inc. (0001412408) (Issuer)

    5/4/26 6:13:59 PM ET
    $PHR
    Real Estate

    Director Goldstein Lainie was granted 1,085 shares, increasing direct ownership by 2% to 51,195 units (SEC Form 4)

    4 - Phreesia, Inc. (0001412408) (Issuer)

    5/4/26 6:13:17 PM ET
    $PHR
    Real Estate

    $PHR
    Leadership Updates

    Live Leadership Updates

    View All

    Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

    Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association's (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, strategies, and individuals advancing patient and HCP engagement through innovative point-of-care (POC) marketing. The two organizations announced a five-year collaboration in August 2025, and in October launched a six-part campaign to engage millions of parents and caregivers with educational and entertaining messages to help keep thei

    3/19/26 9:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Joins the Network Advertising Initiative as a Member, Demonstrating Ongoing Commitment to Industry-Leading Privacy Practices

    Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati

    10/8/24 6:48:00 AM ET
    $PHR
    Real Estate

    Phreesia's Audrey Gato Named as a Top Woman Leader in SaaS

    Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio

    1/16/24 4:05:00 PM ET
    $PHR
    Real Estate

    $PHR
    Financials

    Live finance-specific insights

    View All

    Phreesia Announces First Quarter Fiscal 2027 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2026. "Phreesia had a solid first quarter to build on in fiscal 2027. We entered the new fiscal year with an experienced team, a strong financial profile and continued momentum across several key initiatives, including positioning AccessOne for future growth, the successful launch of our healthcare provider (HCP) marketing offerings and the infusion of AI into the Phreesia operating model," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal 2027 Stakeholder Letter.

    5/27/26 4:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Sets Release Date for Fiscal First Quarter 2027 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal first quarter 2027 financial results after the close of market trading on Wednesday, May 27, 2026. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (833) 461-5787, or (626) 884-3620 for international participants, using conference code number 953036497, or vi

    5/1/26 6:46:00 AM ET
    $PHR
    Real Estate

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    $PHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phreesia Inc.

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    11/12/24 10:34:15 AM ET
    $PHR
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Phreesia Inc.

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    7/8/24 4:37:20 PM ET
    $PHR
    Real Estate

    SEC Form SC 13G/A filed by Phreesia Inc. (Amendment)

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    2/16/24 4:57:01 PM ET
    $PHR
    Real Estate